Who is sponsoring NCT03130270?

NCT03130270 is sponsored by Guilin Medical University, China.

What drugs are being tested in NCT03130270?

Interventions in NCT03130270: Apatinib mesylate tablet.

What condition does NCT03130270 study?

NCT03130270 studies Nasopharyngeal Carcinoma.

Is NCT03130270 still recruiting?

NCT03130270 is currently status unknown. Last updated 16 May 2018.

Last reviewed 2018-05-16 · How we verify

NCT03130270

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma

Status unknown Phase 2 Last updated 16 May 2018

What this trial tests

Phase 2 trial testing Apatinib mesylate tablet in Nasopharyngeal Carcinoma in 29 participants. Status unknown.

Timeline

1 January 2017

Primary endpoint
8 April 2019

8 December 2019

Quick facts

Lead sponsor	Guilin Medical University, China
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	1 January 2017
Primary completion	8 April 2019
Estimated completion	8 December 2019
Sites	4 locations across China

Drugs / interventions tested

Apatinib mesylate tablet

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

Guilin Medical University, China

Who can join

Adults 18 to 70, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is to evaluate the efficacy and safety of Apatinib for later treatment of patients(after second-line treatment for locally recurrent or metastatic nasopharyngeal carcinoma), including overall survival (OS), distant metastasis-free survival (DMFS) and locoregional relapse-free survival (LRRFS); the relationship between EBV DNA copy number and survival after radiotherapy or radiochemotherapy; Quality of life score (QoL); evaluation of drug safety.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.
Liu H, Tang L, Li Y, Xie W, et al · · 2024 · cited 85× · PMID 38254110 · DOI 10.1186/s12943-023-01928-2
Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
Ruan X, Liang JH, Pan Y, Cai R, et al · · 2021 · cited 27× · PMID 34043812 · DOI 10.1002/cncr.33626
Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1.
Knerr JM, Kledal TN, Rosenkilde MM. · · 2021 · cited 10× · PMID 34439235 · DOI 10.3390/cancers13164079
Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.
Mo Y, Pan Y, Zhang B, Zhang J, et al · · 2023 · cited 5× · PMID 38239359 · DOI 10.3389/fimmu.2023.1298418

Verify or expand the search:

Other trials of Apatinib mesylate tablet

Trials testing the same drug.

NCT04350190 — Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma · Phase 2 · completed
NCT03612219 — Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma · Phase 2 · unknown

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other Guilin Medical University, China trials

Trials by the same sponsor.

NCT07141056 — The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03130270 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guilin Medical University, China
Last refreshed: 16 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03130270.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing